Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial.

Abstract

This double-blind, placebo-controlled, cross-over trial demonstrated that Lacteol Fort leads to a statistically significant therapeutic benefit in 50% of patients, when taking into consideration all of the six selected clinical criteria considered representative of IBS.